Have a personal or library account? Click to login

GLP-1 analogues in the treatment of obesity and non-alcoholic fatty liver disease

Open Access
|Feb 2023

Figures & Tables

Comparison of the dosage and the possibility of using the individual GLP-1 receptor agonists available on the Polish market as monotherapy, including the trade names of the products_ LAR: a form of long-acting release preparation

GLP-1 receptor agonistDosing frequencyRegistration in monotherapyTrade name of the product
Exenatide LAR1 × weeknoBydureon
Dulaglutide1 × weekyesTrulicity
Lixisenatide1 × daynoLyxumia
Liraglutide1 × dayyesVictoza
Semaglutide1 × weekyesOzempic
Language: English
Page range: 1 - 8
Submitted on: Apr 5, 2022
Accepted on: Oct 20, 2022
Published on: Feb 28, 2023
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year

© 2023 Kacper Deska, Bartłomiej Bąk, Marcin Kosmalski, Tadeusz Pietras, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.